Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Current Situation of Laser andPhotodynamic Therapy in Exudative Age-Related Macular Degeneration

Eksüdatif Yaşa Bağlı Maküla Dejeneresansında Günümüzde Lazer veFotodinamik Tedav

Pages
225–232
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, current situation of la- ser and photodynamic therapy in ARMD will be updated

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age-Related Macular Degeneration (ARMD), especially its exu- dative form, is an important disease affecting the elderly people of developed countries and causing serious visual loss.
📊
Key Findings & Data:Laser treatment was formerly the leading option like in many other retinal diseases, followed by photody- namic therapy (PDT) for the first time at the beginning of the 2000s, providing an acceptable achievement against the inevi- table visual loss.
💡
Conclusion & Impact:In this article, current situation of la- ser and photodynamic therapy in ARMD will be updated
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age-Related Macular Degeneration (ARMD), especially its exu- dative form, is an important disease affecting the elderly people of developed countries and causing serious visual loss. Many treatment alternatives have been tried up to date, however, the patients were being provided some benefits from the treatment in only recent years. Laser treatment was formerly the leading option like in many other retinal diseases, followed by photody- namic therapy (PDT) for the first time at the beginning of the 2000s, providing an acceptable achievement against the inevi- table visual loss. Although the present treatment approach is anti-VEGF agents, some indications are still valid for laser and PDT in ARMD patients. In this article, current situation of la- ser and photodynamic therapy in ARMD will be updated

Özet

Yaşa bağlı maküla dejeneresansının (YBMD) özellikle eksüdatif formu, gelişmiş toplumlarda yaşlı nüfusunu etkileyen ve ciddi görme kaybına yol açan önemli bir hastalıktır. Tedavisinde bugüne dek birçok alternatif denenmiş, ama ancak son yıllarda hastalara yardımcı olunabilmeye başlanmıştır. Tedavi gelişim sürecinde bütün retina hastalıklarında olduğu gibi başlangıçta laser önemli bir seçenek olmuş, ardından 2000'li yılların başında Fotodinamik Tedavi (PDT) ile ilk kez hastalarda görme kaybının durdurulması başarılabilmiştir. Takip eden dönemde ve günümüzde tedavi yaklaşımı çoğunlukla intravitreal enjeksiyonlar olsa da, hala lazer ve PDT'nin endike olduğu durumlar vardır. Bu yazıda eksüdatif YBMD'de lazer ve PDT'nin günümüzdeki yeri hakkında bilgi verilecektir

🔖

Cite This Article

AKKIN, C. (2015). Current Situation of Laser andPhotodynamic Therapy in Exudative Age-Related Macular Degeneration. Retina-Vitreus, Cilt: 23 - Sayı: 0, 225–232. https://ajindex.com/articles/307897

References (8)

  1. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-8. Persistent and recurrent neovascularization after krypton laser photocoag- ulation for neovascular lesions of age-related macular degeneration. Macu- lar Photocoagulation Study Group. Arch Ophthamol 1990;108:825-31.
  2. Johnson TM, Glaser BM. Focal laser ablation of retinal angiomatous pro- liferation. Retina 2006;26:765-72.
  3. Stoffelns BM, Kramann C, Schoepfer K. Laser photocoagulation and pho- todynamic therapy (PDT) with verteporfin for retinal angiomatous pro- liferation (RAP) in age-related macular degeneration (AMD). Klin Monbl Augenheilkd 2008;225:392-6.
  4. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinalangiomatous proliferation. Arch Ophthalmol 2005;123):1644-50.
  5. Coscas F, Stanescu D, Coscas G, et al. Feeder vessel treatment of choroi- dal neovascularization in age-related macular degeneration. J Fr Ophtal- mol 2003;26:602-8.
  6. Friberg TR, Musch DC, Lim JI, et al. PTAMD Study Group. Prophy- lactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 2006;113:622. Friberg TR, Brennen PM, Freeman WR, et al. PTAMD Study Group. Pro- phylactic treatment of age-related macular degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible patients. Ophthalmic Surg Lasers Imaging 2009; 40:530-8.
  7. Frennesson CI, Bek T, Jaakkola A, et al. Prophylactic Laser Treatment Study Group. Prophylactic laser treatment of soft drusen maculopathy: a prospective, randomized Nordic study. Acta Ophthalmol 2009;87:720-4.
  8. Guymer RH, Brassington KH, Dimitrov P, et al. Nanosecond-laser ap-plication in intermediate AMD: 12-month results of fundus appearance and macular function, Clinical and Experimental Ophthalmology 2013. doi; 10.1111/ceo.12247. Azab M, Boyer DS, Bressler NM, et al. Visudyne in minimally classic cho-roidal neovascularization study group verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthal-mol 2005;123:448-57. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. T